logo image
search icon
Global Preclinical Oncology Models Market

Preclinical Oncology Models Market Size, Share & Trends Analysis Report By Product (Neuroblastoma, Prostate Cancer, Pancreatic Cancer, Breast Cancer, Colorectal Cancer, Bladder Cancer, Kidney Cancer, Liver Cancer, Lung Cancer, Skin Cancer, Others), By Application, By Region, And Segment Forecasts, 2023-2031.

Report ID : 1093 | Published : 2023-05-11 | Pages: 180 | Format: PDF/EXCEL

The Preclinical Oncology Models Market Size is valued at 1218.27 Million in 2022 and is predicted to reach 2678.15 Million by the year 2031 at a 9.3 % CAGR during the forecast period for 2023-2031.

Preclinical Oncology Models Market

The rise of immuno-oncology therapy such as T cell therapy, bispecific antibodies, immune checkpoint modulators, and personalized cancer vaccines compels the need for unique preclinical and translational service solution. Recently advances in Immuno-oncology industry with success of CAR-T Therapy boosted the R&D activities in the oncology industry which boost the demand for preclinical oncology models such as humanized models and syngeneic tumor models. The need for predictive approaches and robust preclinical models to minimize translational failures in immuno-oncology is very high. The factors such as early identification of predictive biomarkers, leveraging phenotypic features of models,and the need of rational design of combination therapies drive the growth of the oncology preclinical models market.

Market Segmentation

The global oncology preclinical models market is segmented on the basis of product, application, and region. Based on the products, the market is divided into Syngeneic Models, Cell Lines Models, Orthotopic Tumor Models, and Others based on application type, the market is segmented into Neuroblastoma, Prostate Cancer, Pancreatic Cancer, Breast Cancer, Colorectal Cancer, Bladder Cancer, Fibrosarcoma, Kidney Cancer, Liver Cancer, Lung Cancer, Lymphoma, Skin Cancer and Others.

Competitive Landscape

Some Of The Key Players In The Preclinical Oncology Models Market:

  • Aragen Bioscience,
  • vivoPharm Pty. Ltd.
  • Bioduro,
  • Crown Bioscience Inc.,
  • Charles River,
  • Champion Oncology, Inc.,
  • Envigo,
  • GenOway S.A.,
  • Hera BioLabs,
  • MI Bioresearch Inc,
  • Pharmatest Services,
  • Taconic Biosciences, Inc.,
  • The Jackson Laboratory

The Preclinical Oncology Models Market Report Scope

Report Attribute

Specifications

Market Size Value In 2022

USD 1218.27 Million

Revenue Forecast In 2031

USD 2678.15 Million

Growth Rate CAGR

CAGR of 9.3 % from 2023 to 2031

Quantitative Units

Representation of revenue in US$ Million and CAGR from 2023 to 2031

Historic Year

2019 to 2022

Forecast Year

2023-2031

Report Coverage

The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends

Segments Covered

By Product, By Application

Regional Scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country Scope

U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia

Competitive Landscape

Aragen Bioscience, vivoPharm Pty. Ltd. Bioduro, Crown Bioscience Inc., Charles River, Champion Oncology, Inc., Envigo, GenOway S.A., Hera BioLabs, MI Bioresearch Inc, Pharmatest Services, Taconic Biosciences, Inc., and The Jackson Laboratory

Customization Scope

Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape.

Pricing And Available Payment Methods

Explore pricing alternatives that are customized to your particular study requirements.

 

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Preclinical Oncology Models Market Snapshot

Chapter 4. Global Preclinical Oncology Models Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Analysis of Key Vendors in Cancer Clinical Trial/Pipeline

4.6. Industry Analysis – Porter’s Five Forces Analysis

4.7. Competitive Landscape

4.8. Major Investment, Partnerships and Collaborations in Cancer Research

Chapter 5. Market Segmentation 1: Product Estimates & Trend Analysis

5.1. Product Type & Market Share, 2020 & 2027

5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2018 to 2027 for the following Product:

5.2.1. Patient-Derived Xenograft Models (PDX)

5.2.2. Cell Line Derived Xenograft Models

5.2.3. Syngeneic Models

5.2.4. Genetically engineered mouse models (GEMMs)

5.2.5. Orthotopic Models

5.2.6. Custom Xenograft and Syngeneic Model

5.2.7. Others

Chapter 6. Market Segmentation 2: Application Estimates & Trend Analysis

6.1. Application Type & Market Share, 2020 & 2027

6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2018 to 2027 for the following Application:

6.2.1. Neuroblastoma

6.2.2. Prostate Cancer

6.2.3. Pancreatic Cancer

6.2.4. Breast Cancer

6.2.5. Colorectal Cancer

6.2.6. Bladder Cancer

6.2.7. Fibrosarcoma

6.2.8. Kidney Cancer

6.2.9. Liver Cancer

6.2.10. Lung Cancer

6.2.11. Lymphoma

6.2.12. Skin Cancer

6.2.13. Others

Chapter 7. Preclinical Oncology Models Market Segmentation 3: Regional Estimates & Trend Analysis

7.1. North America

7.1.1. North America Preclinical Oncology Models Market revenue (US$ Million) estimates and forecasts by product, 2018-2027

7.1.2. North America Preclinical Oncology Models Market revenue (US$ Million) estimates and forecasts by application, 2018-2027

7.1.3. North America Preclinical Oncology Models Market revenue (US$ Million) estimates and forecasts by country, 2018-2027

7.1.3.1. U.S.

7.1.3.2. Canada

7.2. Europe

7.2.1. Europe Preclinical Oncology Models Market revenue (US$ Million) by product, 2018-2027

7.2.2. Europe Preclinical Oncology Models Market revenue (US$ Million) by application, 2018-2027

7.2.3. Europe Preclinical Oncology Models Market revenue (US$ Million) by country, 2018-2027

7.2.3.1. Germany

7.2.3.2. France

7.2.3.3. Italy

7.2.3.4. Spain

7.2.3.5. UK

7.2.3.6. Rest of Europe

7.3. Asia Pacific

7.3.1. Asia Pacific Preclinical Oncology Models Market revenue (US$ Million) by product, 2018-2027

7.3.2. Asia Pacific Preclinical Oncology Models Market revenue (US$ Million) by application, 2018-2027

7.3.3. Asia Pacific Preclinical Oncology Models Market revenue (US$ Million) by country, 2018-2027

7.3.3.1. China

7.3.3.2. India

7.3.3.3. Japan

7.3.3.4. Australia

7.3.3.5. Rest of Asia Pacific

7.4. Rest of World

7.4.1. Rest of World Preclinical Oncology Models Market revenue (US$ Million) by product, (US$ Million)

7.4.2. Rest of World Preclinical Oncology Models Market revenue (US$ Million) by country, (US$ Million) 2018-2027

7.4.2.1. Latin America

7.4.2.2. Middle East & Africa

Chapter 8. Competitive Landscape

8.1. Major Mergers and Acquisitions/Strategic Alliances

8.2. Company Profiles

8.2.1. Aragen Bioscience

8.2.2. vivoPharm Pty. Ltd.

8.2.3. Bisoduro

8.2.4. Crown Bioscience Inc.

8.2.5. Charles River

8.2.6. Champion Oncology, Inc.

8.2.7. Envigo (Inotive Inc.)

8.2.8. GenOway S.A.

8.2.9. Hera Biolabs, Inc.

8.2.10. MI Bioresearch (Labcorp Inc.)

8.2.11. Pharmatest Services

8.2.12. Taconic Biosciences, Inc

8.2.13. The Jackson Laboratory

8.2.14. Reaction Biology(ProQinase GmbH)

8.2.15. Creative Animodel

8.2.16. Biocytogen

8.2.17. Oncodesign Services

8.2.18. WuXi AppTec

8.2.19. Washington Biotechnology Inc.

8.2.20. XenTech.eu

8.2.21. Other Prominent Player List of Other Prominent Players

Global Preclinical Oncology Models Market Segmentation

Global Preclinical Oncology Models Market by Product

  • Patient-Derived Xenograft Models (PDX)
  • Cell Line Derived Xenograft Models
  • Syngeneic Models
  • Genetically engineered mouse models (GEMMs)
  • Orthotopic Models
  • Custom Xenograft and Syngeneic Model
  • Others

Preclinical Oncology Models Market

Global Preclinical Oncology Models Market Based on Application

  • Neuroblastoma
  • Prostate Cancer
  • Pancreatic Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Bladder Cancer
  • Fibrosarcoma
  • Kidney Cancer
  • Liver Cancer
  • Lung Cancer
  • Lymphoma
  • Skin Cancer
  • Others

Global Preclinical Oncology Models Market Based on Region

Europe Preclinical Oncology Models Market Revenue Outlook, 2019-2030

  • K.
  • Germany
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe

North America Preclinical Oncology Models Market Revenue Outlook, 2019-2030

  • U.S.
  • Canada

Asia Pacific Preclinical Oncology Models Market Revenue Outlook, 2019-2030

  • India
  • China
  • Japan
  • South Korea
  • Australia & New Zealand

Latin America Preclinical Oncology Models Market Revenue Outlook, 2019-2030

  • Brazil
  • Mexico
  • Rest of Latin America

Middle East & Africa Preclinical Oncology Models Market Revenue Outlook, 2019-2030

  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

 

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

user icon
office icon
mail icon
call icon

This website is secure, and we do not share your personal information with any third party. Privacy Policy

Need Customization
Need specific information/chapter from the report of the custom data table, graph or complete report? Tell us more.

Frequently Asked Questions

How big is the Preclinical Oncology Models Market Size?

The Preclinical Oncology Models Market is expected to grow at a 9.3 % CAGR during the forecast period for 2023-2031.

Aragen Bioscience, vivoPharm Pty. Ltd. Bioduro, Crown Bioscience Inc., Charles River, Champion Oncology, Inc., Envigo, GenOway S.A., Hera BioLabs, MI

Our Clients

  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo

Media Citations

  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo

Growth opportunities and latent adjacency in Pharmaceuticals

Select Licence Type
$3986
$7500
$10000
$1200
Get Your GTM Strategy

Navigate market entry with channel selection, launch strategy & timeline, and pricing model support.

Equip yourself with the insights needed to develop a winning go-to-market strategy

Get real-time updates and joint control over project direction with our collaborative approach